Skip to main content
Michael Grunwald, MD, Oncology, Charlotte, NC

MichaelRichardGrunwaldMD

Oncology Charlotte, NC

Hematologic Oncology

Physician

Dr. Grunwald is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Grunwald's full profile

Already have an account?

  • Office

    1021 Morehead Medical Dr
    Ste A
    Charlotte, NC 28204
    Phone+1 980-442-2000
    Fax+1 704-355-5800

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2009 - 2013
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 2006 - 2009
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 2006

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2009 - 2026
  • NC State Medical License
    NC State Medical License 2013 - 2025
  • FL State Medical License
    FL State Medical License 2021 - 2023
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Abstracts/Posters

  • Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in...
    Michael R. Grunwald, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Risk of Hemorrhage in Patients with Polycythemia Vera Exposed to Aspirin in Combination with Anticoagulants: Results of a Prospective, Multicenter, Observational Cohor...
    Michael R. Grunwald, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Patient Reported Financial Toxicity in Myeloproliferative Neoplasms
    Michael R. Grunwald, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Ver... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Characteristics Associated with Hydroxyurea Treatment Change in Patients with Polycythemia Vera: An Analysis from the Reveal Study 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Real-World Risk Assessment and Treatment of Patients with Myelofibrosis at Community Oncology Practices in the United StatesClinically Relevant Abstract 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Low-Risk Myelofibrosis Shows Evidence of Disease Progression
    Low-Risk Myelofibrosis Shows Evidence of Disease ProgressionOctober 11th, 2024
  • Sugar Companies Say the Air Is Safe
    Sugar Companies Say the Air Is SafeJuly 8th, 2021
  • HLA-Haploidentical Relative and Matched Unrelated Donor Transplant Lead to Similar Survival Outcomes in MDS
    HLA-Haploidentical Relative and Matched Unrelated Donor Transplant Lead to Similar Survival Outcomes in MDSApril 1st, 2021
  • Join now to see all